STOCK TITAN

Myomo Inc. - $MYO STOCK NEWS

Welcome to our dedicated page for Myomo news (Ticker: $MYO), a resource for investors and traders seeking the latest updates and insights on Myomo stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Myomo's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Myomo's position in the market.

Rhea-AI Summary

Myomo, a wearable medical robotics company, will report financial results for the first quarter ended March 31, 2024 on May 8, 2024. The Company will host a conference call on the same day with prepared remarks by its executives. Participants can pre-register for the call to gain immediate access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.05%
Tags
conferences earnings
-
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO) appoints Heather Getz as a Class II director and chair of its audit committee, bringing extensive corporate experience to the board. Ms. Getz's background in finance, healthcare, and strategic planning will aid Myomo's growth as it accelerates its development in wearable medical robotics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
management
-
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO) reports Q4 total revenue of $4.8 million, up 18% from the prior year. The addition of Medicare Part B patients leads to a record 183 MyoPro orders, up 87%. The company introduces 2024 guidance and aims for a transformational year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
Rhea-AI Summary
Myomo, Inc. (MYO) announces final Medicare DMEPOS fee schedule rates for MyoPro devices, effective April 1, 2024. The average rates for HCPCS codes L8701 and L8702 are $33,480.90 and $65,871.74 respectively. MyoPro officially classified in brace benefit category for lump sum reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.05%
Tags
none
-
Rhea-AI Summary
Myomo, Inc. (MYO) will report Q4 and fiscal year 2023 financial results on March 7, 2024. The conference call will feature remarks by CEO Paul R. Gudonis and CFO David Henry. Participants can pre-register for the call to receive a unique PIN for immediate access. Webcast and call replay details are provided for convenience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.05%
Tags
conferences earnings
-
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO) announced the closing of a registered direct offering of its common stock, resulting in approximately $6.0 million in gross proceeds. The net proceeds will be used to scale up operations to serve Medicare Part B patients, including hiring approximately 50 people over the next six months and increasing clinical, reimbursement, and manufacturing capacity. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO) announced a registered direct offering of 1,578,948 shares of common stock at a purchase price of $3.80 per share, resulting in gross proceeds of approximately $6.0 million. The company expects the proceeds to achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024, assuming certain conditions are met.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
-
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO) announced preliminary revenue and operating metrics for the fourth quarter of 2023, expecting a 14% to 19% increase in revenue compared to the same period a year ago. With a cash balance of $8.7M as of December 31, 2023, the Company has seen a 40% increase in backlog, including Medicare Part B beneficiaries. Myomo's Chairman and CEO, Paul R. Gudonis, anticipates significant revenue growth in 2024, aiming for at least $100 million in annual revenues within the next five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
none
-
Rhea-AI Summary
Myomo, Inc. (NYSE American: MYO) reported Q3 total revenue of $5.1 million, up 28% over the prior year, with 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
Rhea-AI Summary
Myomo, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has proposed fee schedule rates for the MyoPro, a wearable medical robotics device, to be discussed at the HCPCS Public Meeting. The proposed rates for the two HCPCS codes describing the MyoPro are $31,745.42 and $62,457.28. CMS has classified the MyoPro as a brace, enabling reimbursement on a lump sum basis starting from January 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.17%
Tags
none
Myomo Inc.

NYSE:MYO

MYO Rankings

MYO Stock Data

107.11M
14.71M
13.93%
42.65%
2.47%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
BOSTON

About MYO

myomo's mission is to enable individuals to overcome their paralysis by providing innovative, myoelectric orthotics and support services. we are committed to working with healthcare professionals to deliver high quality outcomes and patient satisfaction through research collaborations and continuing education programs. the company empowers persons with a neuromuscular disability to perform functional activities at home, at work, and in the community, resulting in an improved quality of life and lower healthcare costs.